Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the <scp>PIONEER</scp> 11 and 12 randomised controlled trials
Oral semaglutide reduces HbA<sub>1c</sub> and body weight across a range of baseline subgroups in a Chinese population with type 2 diabetes without any unexpected additional safety concerns. These results support the use of oral semaglutide in a broad population in clinical practice.
Authors
- Linong Ji (ORCID: https://orcid.org/0000-0003-1305-1598)
- Bingjie Zhang (ORCID: https://orcid.org/0000-0002-3686-3962)
- Guoyue Yuan (ORCID: https://orcid.org/0000-0003-0822-6066)
- Wenyan Liu (ORCID: https://orcid.org/0000-0002-6714-520X)
- Jun Liu (ORCID: https://orcid.org/0000-0002-0843-5127)
- Zewei Shen
Institutions
- Jiangsu University (CN)
- Peking University (CN)
- Fudan University (CN)
- Affiliated Hospital of Jiangsu University (CN)
- Peking University People's Hospital (CN)
- Novo Nordisk (Italy) (IT)
- Obstetrics and Gynecology Hospital of Fudan University (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-08-22
- DOI
- https://doi.org/10.1111/dom.70031
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk